IP Library › Granted Patent US 11,504,354
Granted Patent B1
US 11,504,354 · App. 17/860,682 · Granted Nov 22, 2022

Chlorinated tetralin compounds and pharmaceutical compositions

Inventors: Kristin Patterson (Stamford, CT); Mark Hatcher (Stamford, CT)
A61K31/417A61K9/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,504,354
App. No.
17/860,682
Granted
Nov 22, 2022
Kind
B1
Abstract

The present disclosures are directed to chlorinated tetralin compounds and pharmaceutical compositions.

Claims (13)

1. A pharmaceutical composition comprising a compound of Formula IA which is

or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition according to claim 1 , wherein the compound of Formula IA is present in an amount of about 1 μg to about 500 μg.

3. The pharmaceutical composition according to claim 1 , wherein the compound of Formula IA is present in an amount of about 5 μg to about 500 μg.

4. The pharmaceutical composition according to claim 1 , wherein the compound of Formula IA is present in an amount of about 10 μg to about 250 μg.

5. The pharmaceutical composition according to claim 1 , wherein the compound of Formula IA is present in an amount of about 10 μg to about 100 μg.

6. The pharmaceutical composition according to claim 1 , wherein the compound of Formula IA is present in an amount of about 10 μg to about 50 μg.

7. The pharmaceutical composition according to claim 1 , wherein the compound of Formula IA is present in an amount of about 12.5 μg to about 50 μg.

8. The pharmaceutical composition according to claim 1 , further comprising a gamma-secretase inhibitor selected from the group consisting of nirogacestat or a pharmaceutically acceptable salt thereof, crenigacestat or a pharmaceutically acceptable salt thereof, AL101 or a pharmaceutically acceptable salt thereof, AL102 or a pharmaceutically acceptable salt thereof, semagacestat or a pharmaceutically acceptable salt thereof, avagacestat or a pharmaceutically acceptable salt thereof, and ianabecestat or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition according to claim 1 , further comprising nirogacestat or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition according to claim 1 , further comprising a pharmaceutically acceptable carrier.

11. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is for oral administration.

12. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a tablet.

Continuity (3)
Provisional Application 63365125 · May 20, 2022
Provisional Application 63263635 · Nov 5, 2021
Provisional Application 63241844 · Sep 8, 2021
Cited By (3)
US 12,234,210 US 12,247,012 US 12,599,587